👥 The partnership combines AGC Biologics’ expertise in development and manufacturing with BioConnection’s aseptic filling capabilities.
💊 They provide a “gene to vial” value chain service with a single contract and project management team.
🌍 Developers now have access to secure services for development, manufacturing, freeze-drying, and aseptic filling.
⚠️ This partnership is aimed at addressing the needs of the industry in light of the proposed U.S. BIOSECURE Act.
🔒 The act aims to ensure secure supply chains by prohibiting contracts with companies that pose a threat to national security.
💡 By joining forces, AGC Biologics and BioConnection offer integrated manufacturing solutions for biopharmaceutical development.
Introduction:
AGC Biologics, a contract development and manufacturing organization (CDMO), has partnered with BioConnection, a contract manufacturing organization (CMO), to offer integrated biopharmaceutical development and manufacturing services. This partnership aims to address the ongoing needs of the industry and provide a secure supply of services for developers.
- The partnership between AGC Biologics and BioConnection will provide end-to-end biopharmaceutical development and manufacturing capabilities.
- The companies offer a “gene to vial” value chain service with a single contract and project management team for the entire project lifecycle.
- This strategic partnership addresses the industry’s needs in light of the proposed U.S. BIOSECURE Act, which aims to restrict contracts with biotechnology companies of concern to national security.
- The combined resources and facilities of AGC Biologics and BioConnection in Japan, the U.S., and Europe offer a secure supply of services, including development, manufacturing, freeze-drying, and aseptic filling.
- The partnership aims to provide reliable facilities for global pharmaceutical companies and developers, offering a new end-to-end solution under one contract with AGC Biologics.
Conclusion:
The partnership between AGC Biologics and BioConnection allows for the integration of biopharmaceutical development and manufacturing services, providing a secure and reliable solution for developers in the face of regulatory changes. This collaboration addresses the need for end-to-end services and offers a combined expertise in gene to vial production. It also highlights the importance of secure supply chains in the biopharmaceutical industry. Overall, this partnership can contribute to the advancement and availability of biodrug product development and manufacturing.
